Search
for

    Sort by

    Community Join

    990-1000 / 1000+ results

      community The best vehicle/carrier for RU58841

      in Treatment  2 upvotes 2 years ago
      The conversation is about the best vehicle for RU58841, comparing trichosol and Garnier/Vichy Stemoxydine, avoiding propylene glycol (PG) or ethanol due to previous scalp damage. The user is also seeking sources for these products in the EU.

      community Ru58841 2% ED 9 month progress

      in Progress Pictures  17 upvotes 3 years ago
      A user shared their 9-month progress using RU58841 at 2% daily for hair regrowth, initially starting at 5% but reducing the dose due to early signs of gynecomastia, which has since mostly resolved. They achieved their goal of regrowing hair at the temples and hairline.

      community FDA approves Cassiopea's WINLEVI (CB-03-01, 1% formulation) for Acne

      in Technology  33 upvotes 5 years ago
      The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.

      community RU-58841 Lung Disease Possibility | Chest pain, "heart issues", etc

      in Treatment  20 upvotes 2 years ago
      Some users of RU-58841 report cardiovascular symptoms like heart palpitations and chest tightness, which may be linked to its metabolites causing lung disease. The safety of RU-58841 is uncertain due to lack of long-term data and concerns about product purity, especially from gray market sources.

      community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance

      in Research/Science  124 upvotes 2 years ago
      The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

      community KX-826 1% Phase II Results from China Just Dropped

      in Research/Science  36 upvotes 1 year ago
      KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.

      community SUBE3 for sale in the gray market?

      in Chat  4 upvotes 1 year ago
      SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.